Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Innovations to accelerate vaccine development and manufacture (Inno4Vac)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Germany,Germany,Germany,Germany,Italy,Germany,Germany,Germany,Germany,Germany,Norway,Norway,Sweden,Sweden,Switzerland,Belgium,Belgium,France,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Denmark,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Portugal,Portugal,Denmark
Call: Innovations to accelerate vaccine development vaccine development and manufacture (H2020-JTI-IMI2-2020-20-two-stage, 2020)
Start date: 2021-09-01
End date: 2027-02-28
Duration (months): 66.0
Total project cost (EUR): 39342552.0
EU funding (EUR): 18600000.0
Participants: 42
Project status: SIGNED

Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling persistent scientific bottlenecks in vaccine development and for de-risking and accelerating this process. To reach this aim the project is divided into four interlinked subtopics. In Subtopic 1, artificial intelligence in combination with big data analysis and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Subtopic 2 will develop new and improved controlled human infection models (CHIM) against influenza, RSV and C. difficile that will enable early vaccine efficacy evaluation. Subtopic 3 will contribute to the development of cell-based human in vitro 3D models that resemble the in vivo situation of an infection at the mucosa and more reliably predict immune protection. These models will be combined with the development of related functional immune assays for clinically relevant (surrogate) endpoints. Finally, Subtopic 4 will develop a modular one-stop computational platform for in silico modelling of vaccine bio-manufacturing and stability testing. In parallel to the scientific-technical work, the partners will develop strategies and roadmaps for positioning the newly developed models in the regulatory framework and integrating them into pharmaceutical vaccine development. The overall workplan is underpinned by horizontal activities on coordination/management and dissemination/communication, including data management and future sustainability. To achieve these ambitious objectives, Inno4Vacc has assembled a multidisciplinary consortium from academic and research institutions, industries, regulatory bodies, and vaccine R&D alliances. This unique partnership brings together clinical, immunological, microbiological, systems biology, mathematical models, and regulatory expertise and includes world-leaders in each respective field.

Keywords: controlled human infection models,artifical intelligence,modelling,in vitro models,mucosa,manufacturing
Reducing the unemployment rate amongst blind people by introducing a working tool that increases their autonomy and productivity. (Tactonom)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-09-01
End date: 2019-02-28
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Our objective is to decrease the unemployment rate amongst blind people (75 % in Europe; Source RNIB) by 10 % until 2028 by increasing their autonomy and productivity in the work environment. This is achieved by introducing a tool for blind people that enables the access to any information without the help of others. This is achieved with the Tactonom, a tactile graphics display that is composed of 10.591 tactile points in a DIN A4 sized touch field. Plugged into a PC the tactile display performs the same task as a screen would for a sighted person. The new technology grants blind people instant access to information like tables (Excel), charts, graphs, diagrams, images, maps, forms, graphics, icons, flow charts, mind maps, and many more. For blind people the ability to instantly access such information is no less than a paradigm shift. This is because the currently existing output technologies (single line Braille Displays and Screen Readers) are only able to output text based information. This is insufficient because a vast amount of information is not text based but graphic visualization. However, these are not instantly accessible for blind people today. This diminishes the autonomy and productivity of blind people and blocks their access to many job profiles. The Tactonom is a disruptive technology for two reasons: 1) it is the only technology that enables the access to all information types. 2) the new patented technology is 5 times cheaper per tactile than its cheapest competitor. Both benefits combined will ensure that the 2.5 M blind and many of the 23.8 M visually impaired people (Source WHO) living in Europe can take active part in society and will not be left behind by the digital revolution. Also, blind people will be able to access new job profiles which leads to a strong reduction in the unemployment rate. The technology exists as a prototype and has currently achieved the technology readiness level TRL 5.

Keywords: assistive technologies,blind people,braille,tactile graphics,unemployment,working tool,visually impaired people
Lipid droplet hypertrophy : the link between adipocyte dysfunction and cardiometabolic diseases (SPHERES)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Sweden,France,France,France
Call: ERC Synergy Grant (ERC-2019-SyG, 2019)
Start date: 2020-09-01
End date: 2026-08-31
Duration (months): 72.0
Total project cost (EUR): 9741774.25
EU funding (EUR): 9741774.0
Participants: 5
Project status: SIGNED

The goal of SPHERES is to understand the dynamics and consequences of adipocyte hypertrophy (enlargement) through investigation of its large lipid droplet (LD). The adipocyte LD is a unique organelle specialized in storing energy in triglycerides (TGs). Its surface is composed of a phospholipid monolayer and specific LD-associated proteins (such as perilipins, CIDEs and lipases), which jointly regulate LD stability and TG turnover. Adipocyte hypertrophy due to an increase in LD size may, irrespective of body fat mass, cause a wide range of pathological conditions, notably cardiometabolic diseases. SPHERES PIs (Langin, Rydén, Antonny) postulate that disturbances in the interactions between LD proteins and LD lipid composition lead to adipocyte hypertrophy and its deleterious consequences. We have identified three fundamental unanswered questions: what determines the unique structure and dynamics of large LD; why does increased LD size alter the functional phenotype of the adipocyte; which factors cause inter-individual variations in LD size. To address these questions, SPHERES gathers expertise in clinical and cellular studies on human adipocytes, in/ex vivo investigations in mouse models, and biophysical analyses of LDs. At the core of this application is the development of beyond-state-of-the-art models and methods (spheroid cultures, native large LD preparation and reconstitution, proximity labelling of LD proteins, gene editing in cell and mouse models, and advanced LD imaging), only achievable through joint integrated effort of the PIs and co-workers. Spanning from molecular, cellular to the whole-body level, SPHERES will link new knowledge on the formation and maintenance of large adipocyte LDs to the deleterious impact of adipocyte hypertrophy. Altogether, SPHERES has a strong potential to discover novel pathogenic mechanisms, leading to a better understanding of highly prevalent diseases and identification of therapeutic strategies targeting adipocytes.
New Blue Revolution through a pioneering pathogen-trapping technology based on bioselective hydrogel-forming proteins (PathoGelTrap)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Ireland,Spain,Italy,Spain,Poland,France
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2019)
Start date: 2020-06-01
End date: 2023-11-30
Duration (months): 42.0
Total project cost (EUR): 2996437.5
EU funding (EUR): 2996437.5
Participants: 7
Project status: SIGNED

Aquaculture is a key player to ensure future food and nutrition security. However, intensive farming models are leading to a dramatic increase in infection outbreaks that drastically impact fish health, food production, the environment and this industry's bottom line. Current strategies to control and prevent infections in intensive aquaculture (mainly vaccines and antibiotics) have important drawbacks, which pose a great challenge to the future sustainability of global fish production. Here, we propose to transform the aquaculture future through a paradigm change in infectious-disease management practices by providing industry with a pioneering pathogen-trapping technology, PathoGelTrap, able to target and remove specific pathogens directly from water. Going way beyond the state of the art, we will use the current knowledge on self-assembling properties of the Liquid-Liquid Phase Separation proteins (LLPS) and affibodies (AFB) to rationally design a chimeric biomimetic material (LLPS-AFB chimera) that will efficiently recognize and trap fish pathogens (both viruses and bacteria) directly in the water and inactivate them. Thanks to the versatility offered by LLPS proteins, we propose to provide the industry with two different solutions: i) PathoGelTrap Liquid (only for closed fish farms): here the LLPS-AFB monomeric protein acts as a flocculant agent to be added in situ, i.e. directly into the fish-farm water. The protein will bind the targeted pathogens in the water and later self-assemble into liquid droplets that will evolve into hydrogels, which will drag in turn the pathogen to the bottom; ii) PathoGelTrap Filter: here we will cast a customized LLPS-AFB hydrogel to be used as a preformed filter that will trap the pathogens as they pass through the regular aquaculture filtration systems. This proposal represents a significant advance in biomaterial engineering opening the door for a revolutionary approach for infectious disease control in Aquaculture.

Keywords: aquaculture health management,affibody,liquid liquid phase separation proteins
DEMONSTRATING LIQUID HYDROGEN FOR THE MARITIME SECTOR (HyShip)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Innovation actions
Partnership: FCH2 (Art-187)
Countries involved: Germany,Norway,Switzerland,Norway,Norway,Greece,France,France,Netherlands,United Kingdom,Panama
Call: Demonstration of liquid hydrogen as a fuel for segments of the waterborne sector (H2020-JTI-FCH-2020-1, 2020)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 10796560.0
EU funding (EUR): 7993942.0
Participants: 19
Project status: SUSPENDED

The develops and validates approaches to build (3MW) and scale (to 20MW) fuel cell approaches that lower operational cost (capex) and design cost of LH2 PEM operations. We integrate the technical solutions in a larger socio-technical system, in cooperation with linked projects and considerable investments that the project will help generate, with the result of providing what could be the first European maritime supply chain for LH2. This is helped by having the demonstrator as one of two planned sister ships that will connect a new hydrogen production facility with LH2 demand in a series of vessels. Most of these new vessels are in planning stages, and one of them are now built for operation in September 2021 (which then will be the first LH2 ship in operation, with a smaller 400 kW system, by consortia member Norled). HyShip combines the state of the art in ship design (building on the RHODA-method to incorporate logistics and fuel supply in the design process), intelligent energy management systems (lowering capex) and a range of novel conceptual designs of LH2 systems. The project will generate considerable value for Europe, both as its generic approaches will lower cost and time for new vessel projects, but also through its initiative to initiate a scalable distribution system where operators have stable and low-cost access to CertifyHy’ed Green H2. Behind the project is a combination of leading expertise on LH2, energy systems, business models and ship design. Industry partners cover the energy system (Kongsberg Maritime), LH2 systemsThis proposal, HyShip, is a response to topic “FCH-01-6-2020: Demonstration of liquid hydrogen as a fuel for segments of the waterborne sector”, in the “Fuel Cells and Hydrogen Joint Undertaking”. We propose development and validation of a 2MW fuel cell liquid hydrogen ship, used in a hydrogen bunkering and supply chain, along with developing business models and the innovation ecosystem for multiple vessels and European regions.

Keywords: liquid hydrogen,pem fuel cells,zero emission shipping
Dynamic ubiquitin signalling coordinates transcriptional reprogramming in plant immunity (UbRegulate)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: United Kingdom
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-09-01
End date: 2026-08-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

Dynamic regulation of gene expression is vital for all organisms and enables them to respond to the ever-changing environment. Plant cells display dramatic reprogramming of the transcriptome in response to pathogen attack, ensuring prioritisation of immune responses over normal cellular functions. The immunizing hormone salicylic acid (SA) plays indispensable roles in this process, establishing long-lasting disease resistance against future pathogen attack. Chemical and genetic approaches that impinge on SA signalling have been developed to combat economically costly plant diseases that threaten future food security. However, these protection strategies are often environmentally unsustainable or have penalties on plant growth and yield. Understanding how SA reprograms the transcriptome to establish durable immunity will enable the urgent design of improved sustainable technologies for crop protection. My team recently pioneered discoveries that demonstrate SA employs the small post-translational modifier, ubiquitin, to establish durable immunity. SA induces dynamic modification of regulatory proteins with ubiquitin chains of diverse linkage types, generating the potential to control their functions and activities. Understanding the relevance of distinct ubiquitin chain types and their protein targets is a major challenge and is only in its infancy in plants. The ‘UbRegulate’ project will reveal how SA-induced ubiquitin signalling: (i) engages the transcriptional machinery and reveal its potential for exploitation by agrichemical biology; (ii) avoids transcription-induced genome instability; (iii) orchestrates chromatin permissiveness to allow gene expression; and (iv) utilises diverse chain linkage types to establish durable, broad-spectrum immunity. In addition to advancing fundamental insights into dynamic ubiquitin signalling, this ambitious project will reveal how ubiquitin signalling can be harnessed to revolutionise plant protection strategies.

Keywords: salicylic acid,plant immunity,ubiquitin,proteasome,post translational modification
On-chip Photonic Cluster State Generation (OPHOCS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-03-01
End date: 2019-02-28
Duration (months): 24.0
Total project cost (EUR): 200194.8
EU funding (EUR): 200194.8
Participants: 1
Project status: CLOSED

The MSCA Individual fellowship project OPHOCS – On-chip Photonic Cluster State Generation focuses on the realization and investigation of large cluster states of entangled single photons with applications in quantum information processing. The project will progress recent developments of quantum dot spin qubits as the entanglement resource, which may be scaled up to a large cluster state by employing state-of-the-art nanophotonic devices to efficiently boost the photon generation efficiency. A highly entangled many-photon cluster state is an eagerly sought after fundamental resource enabling measurement-based quantum-information processing. Here computation algorithms are carried out only by single-qubit measurements combined with classical feed-forward operations on the large-scale cluster state. This feature makes such a one-way quantum computer highly desirable as it critically reduces the requirements for quantum computation. Recent, first proof-of-principle implementations elucidate its potential but are limited in their scalability. The proposed research will facilitate self-assembled semiconductor quantum dots as a scalable photonic resource by exploiting their unique ability for the generation of highest purity indistinguishable photons with unprecedented high efficiencies. This resource will be directly integrated into nanophotonic waveguide devices, and the inherently strong light-matter interaction exploited to demonstrate efficient spin-photon interfaces for high rate, high fidelity cluster state generation. With this architecture we will establish a solid-state device for quantum information science, with the immediate target of generating, for the first time, on-chip photonic cluster states with n>10.

Keywords: photonic integrated circuits,self assembled quantum dots,entanglement,single photon,cluster state generation,photonic crystal cavity,photonic crystal waveguide,electron spin qubit
Adaptive Management of Barriers in European Rivers (AMBER)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Protection of the environment, sustainable management of natural resources, water , biodiversity and ecosystems
Action type: Research and Innovation actions
Countries involved: Spain,Spain,Ireland,Italy,Germany,Ireland,Germany,Switzerland,Sweden,Belgium,Poland,Poland,France,France,Netherlands,Denmark,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: More effective ecosystem restoration in the EU (H2020-SC5-2015-two-stage, 2015)
Start date: 2016-06-01
End date: 2020-09-30
Duration (months): 52.0
Total project cost (EUR): 6238103.75
EU funding (EUR): 6020172.75
Participants: 22
Project status: CLOSED

Rivers rank among some of the most threatened ecosystems in the world, and are the focus of costly restoration programmes that cost billions to taxpayers. Much of Europe depends on water from rivers for drinking, food production, and the generation of hydropower, which is essential for meeting the EU renewable energy target. Yet only half the EU surface waters have met the WFD’s 2015 target of good ecological status, due in part to the fragmentation of habitats caused by tens of thousands of dams and weirs which also pose a flood hazard. Some barriers are old and out of use, but may have historical value, while the life span of others will soon come to an end and may need to be removed. But barriers also provide energy, water, fishing and leisure opportunities, and may also help to prevent the spread of aquatic invasive species. Improving stream connectivity has been flagged as one of the priorities for more efficient stream restoration but effective rehabilitation of ecosystem functioning in European rivers needs to take the complexity and trade-offs imposed by barriers into account. AMBER will deliver innovative solutions to river fragmentation in Europe by developing more efficient methods of restoring stream connectivity through adaptive barrier management. The project seeks to address the complex challenge of river fragmentation through a comprehensive barrier adaptive management process, based on the integration of programme design, management, and monitoring to systematically test assumptions about barrier mitigation, adapt and learn.

Keywords: water framework directive,habitats directive,floods directive,hydropower,river fragmentation,connectivity,barriers,adaptive management,stream ecology,mitigation
A revolutionary, cost effective, ultra-compact proton therapy system for cancer treatment (HIL PT System)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-10-01
End date: 2022-11-30
Duration (months): 38.0
Total project cost (EUR): 3356152.5
EU funding (EUR): 2349306.75
Participants: 1
Project status: SUSPENDED

Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030. Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck, central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery. Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy cancer cells. Proton therapy can be used alone or combined with other treatments e.g. radiation therapy, surgery, chemotherapy, and/or immunotherapy. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical demand. HIL has developed an ultra-compact, high-performance system for Proton Therapy. HIL’s advanced particle accelerator and beamline technologies aim to make PT widely accessible by offering highly cost-effective single-room solutions. During the innovation project, HIL intends to scale-up the performance of the laser proton accelerator, customise the design of the delivery system, and clinically validate the laser proton performance. The project will also enable crucial commercial activities including implementation of IP strategy, communication strategy and scouting potential customers.

Keywords: proton therapy,cancer treatment,nanotechnology,high intensity laser,spatial efficiancy